Paul Uppal – 2014 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Paul Uppal on 2014-05-02.

To ask the Secretary of State for Health, what representations he has received on the applicability of the end-of-life criteria to the National Institute for Health and Care Excellence’s appraisal of abiraterone acetate for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy.

Norman Lamb

Since January 2013, the Department has received four questions from hon. Members, including his own, regarding the applicability of end-of-life criteria in the National Institute for Health and Care Excellence’s appraisal of abiraterone (Zytiga) for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy.

In addition, we have received one letter from an hon. Member regarding this particular appraisal more generally.